Contrave and high blood pressure: the exact label boundary

Contrave is contraindicated for people with uncontrolled hypertension. Its label also says blood pressure and heart rate can rise during treatment, including in people whose hypertension is controlled. The label does not supply a single numerical cutoff that lets a web page classify an individual’s pressure as controlled or uncontrolled; the prescriber must review the actual history and measurements.¹

Contrave combines naltrexone and bupropion. The blood-pressure question belongs to that exact combination product, not to every medicine offered by a weight-management clinic. The Contrave versus Qsymia guide covers product choice; this article focuses on the hypertension boundary in Contrave’s own label.

Two label statements serve different purposes

The contraindication in section 4 names uncontrolled hypertension. Section 5.5 is a broader warning: blood pressure and heart rate can increase, and the label calls for baseline and regular assessment, particularly where hypertension is already controlled. A person should not infer that having any hypertension automatically equals the contraindication, or that a single reassuring reading makes the warning irrelevant.¹

In controlled studies, mean group differences from placebo were most prominent during the first 12 weeks. The label reports average systolic differences of about 1.8–2.4 mm Hg and diastolic differences of about 1.7–2.1 mm Hg at various points in that period. Those are group averages, not an upper limit for an individual rise. The trials also excluded some people with recent serious cardiovascular events or conditions, so their group numbers should not be stretched to every clinic population.¹

Make the record more useful than a yes/no questionnaire

Bring the established hypertension diagnosis, readings with dates and context, current medicines, and any prior reactions to bupropion-containing products. These items let the prescriber interpret the label in relation to the person rather than asking a website to diagnose control. Also clarify which clinician manages the existing blood-pressure condition and how new measurements will be shared. Contrave is a different product from Wellbutrin even though both involve bupropion; our product-identity comparison explains why the exact prescription matters.¹

If a practice states “Contrave is safe for high blood pressure” without distinguishing controlled from uncontrolled hypertension, ask for the basis of that assessment and a plan for reviewing a change. The same question should be asked before an automated renewal. A medical weight-management provider directory can identify practices, but only a clinician with the actual record can decide whether this labeled contraindication applies.

Why a trial average cannot be a safety threshold

The label’s mean pressure differences describe averages across assigned groups at measured visits. They do not describe the largest individual change, a normal range for a particular person, or a diagnosis of hypertension control. Some trials also excluded people with recent myocardial infarction or stroke, life-threatening arrhythmias, or congestive heart failure. A practice should not use the trial mean to dismiss a person’s measured change or assume that excluded populations were directly studied.¹

Similarly, “uncontrolled” is a clinical status, not a number invented by this article. The label does not define a single universal reading at which the contraindication turns on. The prescribing clinician can reconcile repeated measurements, existing diagnoses and treatment, and other cardiovascular facts. A website that offers a one-reading decision rule would be more precise than the source allows. The record-based answer may be different from a checkout quiz’s binary box.¹

Compare the right products and people

Contrave includes bupropion, which has its own relevant warnings and interactions, plus naltrexone. The clinician should know about other bupropion-containing products rather than assuming a brand change is a new ingredient exposure. However, a Wellbutrin label cannot stand in for Contrave’s weight-management evidence. The Contrave-versus-Wellbutrin article separates those identities; the phentermine pressure article handles another drug’s different labeling.

Ask who is responsible for reviewing blood-pressure information when a weight prescription and existing hypertension care involve different practices. A documented route to share results is more useful than a vague “monitor yourself” statement. The prescriber can set a plan based on the complete record; this article only establishes why the label requires one.